Publications by authors named "Alan Rong"

Claim this Profile
I
Informative event rate in study determination, study design, and interim analysis monitoring with non-proportional hazards.
Shufang Liu, Kentaro Takeda, Alan Rong

J Biopharm Stat· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A basket trial design based on constrained hierarchical Bayesian model for latent subgroups.
Kentaro Takeda, Atsuki Hashimoto, Shufang Liu, Alan Rong

J Biopharm Stat· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison Between Simultaneous and Sequential Utilization of Safety and Efficacy for Optimal Dose Determination in Bayesian Model-Assisted Designs.
Ran Li, Kentaro Takeda, Alan Rong

Ther Innov Regul Sci· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An adaptive biomarker basket design in phase II oncology trials.
Shufang Liu, Kentaro Takeda, Alan Rong

Pharm Stat· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TITE-gBOIN: Time-to-event Bayesian optimal interval design to accelerate dose-finding accounting for toxicity grades.
Kentaro Takeda, Qing Xia, Shufang Liu, Alan Rong

Pharm Stat· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Constrained hierarchical Bayesian model for latent subgroups in basket trials with two classifiers.
Kentaro Takeda, Shufang Liu, Alan Rong

Stat Med· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Study design of single-arm phase II immunotherapy trials with long-term survivors and random delayed treatment effect.
Chenghao Chu, Shufang Liu, Alan Rong

Pharm Stat· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimation of delay time in survival data with delayed treatment effect.
Wei Li, Sophie Yu-Pu Chen, Alan Rong

J Biopharm Stat· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker threshold adaptive designs for survival endpoints.
Guoqing Diao, Jun Dong, Donglin Zeng, Chunlei Ke, Alan Rong

J Biopharm Stat· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Weighted log-rank test for time-to-event data in immunotherapy trials with random delayed treatment effect and cure rate.
Shufang Liu, Chenghao Chu, Alan Rong

Pharm Stat· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects.
Guoqing Diao, Donglin Zeng, Joseph G Ibrahim, Alan Rong, Oliver Lee

J Biopharm Stat· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pattern mixture models for clinical validation of biomarkers in the presence of missing data.
Fei Gao, Jun Dong, Donglin Zeng, Alan Rong, Joseph G Ibrahim

Stat Med· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Flexible combination of multiple diagnostic biomarkers to improve diagnostic accuracy.
Tu Xu, Yixin Fang, Alan Rong, Junhui Wang

BMC Med Res Methodol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer.
J Randolph Hecht, Jean-Yves Douillard, Lee Schwartzberg, Axel Grothey, Scott Kopetz, Alan Rong

Cancer Treat Rev· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RAS mutations in colorectal cancer.
Jean-Yves Douillard, Alan Rong, Roger Sidhu

N Engl J Med· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Jean-Yves Douillard, Kelly S Oliner, Salvatore Siena, Josep Tabernero, Ronald Burkes, Alan Rong

N Engl J Med· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of progression-free survival as a surrogate endpoint for survival in chemotherapy and targeted agent metastatic colorectal cancer trials.
Roger Sidhu, Alan Rong, Steve Dahlberg

Clin Cancer Res· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Marc Peeters, Timothy Jay Price, Andrés Cervantes, Alberto F Sobrero, Michel Ducreux, Alan Rong

J Clin Oncol· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis